Chronic Hepatitis C, Endothelial Dysfunction, Atherosclerosis
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: Monoinfected patients by with HIV; or HCV-HIV co-infected; using antiretroviral therapy; who signed an consent form.
Exclusion criteria
Exclusion criteria: history of diabetes mellitus; acute myocardial infarction; renal insufficiency (creatinine current> 1.5); stroke; clinical signs and / or laboratory evidence of liver cirrhosis (ascites, hepatic encephalopathy present or recent upper gastrointestinal bleeding, esophageal varices present, liver ultrasound with signs suggestive of cirrhosis, biopsy Metavir F4); current pregnancy; recent use (last 30 days) of: statins, fibrates, hormone replacement therapy, sulfonamides (sulfamethoxazole, sulfadiazine), vitamin supplements, or similar of folinic acid and / or folic acid; Individuals with restriction or inability to understand and decide for their participation in the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary endpoint is the vascular response of the brachial artery during reactive hyperemia, as measured by Doppler ultrasound before and after the intervention. The variation of at least 20% of the flow is considered positive outcome. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcomes are changes in biochemical and hemodynamic variables at baseline and after interventions. Laboratory analysis (serum): homocysteine,folic acid, vitamin B12, creatinine, fasting glucose, cholesterol, (total, high and low density), triglycerides. Will be measured blood pressure, heart rate, weight, height. | — |
Countries
Brazil
Contacts
Hospital Universitario de Santa Maria;Hospital de Clinicas de Porto Alegre